Skip to main content

Skye Bioscience, Inc 10-Q for FY2026 Q3

Skye Bioscience, Inc. (SKYE)

10-Q 2026-11-13 For: 2026-09-30
View Original
Added on November 13, 2026

About this 10-Q

Skye Bioscience, Inc filed this 10-Q on November 13, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Skye Bioscience, Inc. terminated the CBeyond trial, paused nimacimab research and development, and entered a conditional agreement to acquire Redx. Concurrent financing is expected to provide approximately $103.9 million, potentially increasing to $108.9 million. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Net income
$69.13K
compared with a net loss of $12.75M a year earlier
Diluted EPS
$0.01
compared with -$2.57 a year earlier